VISEN Pharmaceuticals (HKG:2561)
Hong Kong
· Delayed Price · Currency is HKD
44.80
-2.00 (-4.27%)
May 28, 2025, 4:08 PM HKT
VISEN Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Other Revenue | 111.41 | -1.67 | -2.3 |
| Revenue | 111.41 | -1.67 | -2.3 |
| Gross Profit | 111.41 | -1.67 | -2.3 |
| Selling, General & Admin | 80.27 | 79.94 | 177.45 |
| Research & Development | 78.51 | 57.69 | 179.55 |
| Operating Expenses | 158.78 | 137.63 | 357 |
| Operating Income | -47.37 | -139.3 | -359.29 |
| Interest Expense | -0.2 | -0.32 | -0.62 |
| Interest & Investment Income | 8.1 | 11.15 | 5.57 |
| Currency Exchange Gain (Loss) | -3.96 | 4.71 | 79.78 |
| Other Non Operating Income (Expenses) | -18.29 | -16.28 | -14.3 |
| EBT Excluding Unusual Items | -61.72 | -140.05 | -288.86 |
| Gain (Loss) on Sale of Assets | - | -0.24 | -0.1 |
| Other Unusual Items | -109.01 | -109.28 | - |
| Pretax Income | -170.72 | -249.57 | -288.97 |
| Net Income | -170.72 | -249.57 | -288.97 |
| Net Income to Common | -170.72 | -249.57 | -288.97 |
| Shares Outstanding (Basic) | 9 | 9 | - |
| Shares Outstanding (Diluted) | 9 | 9 | - |
| EPS (Basic) | -18.28 | -26.72 | - |
| EPS (Diluted) | -18.28 | -26.72 | - |
| Free Cash Flow | -218.27 | -271.83 | -248.03 |
| Free Cash Flow Per Share | -23.37 | -29.10 | - |
| EBITDA | -46.48 | -137.79 | -357.55 |
| D&A For EBITDA | 0.89 | 1.51 | 1.74 |
| EBIT | -47.37 | -139.3 | -359.29 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.